Results 171 to 180 of about 13,758 (226)

Correction to "Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)". [PDF]

J Surg Oncol
europepmc   +1 more source

Predicting postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: retrospective cohort study. [PDF]

BJS Open
Martin-Roman L, Kusamura S, Guaglio M, Colletti G, Cavalleri T, Deraco M, Baratti D.   +6 more
europepmc   +1 more source

Retrospective evaluation of anesthesia management and clinical outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [PDF]

BMC Anesthesiol
Kaya A, Karahan MA.
europepmc   +1 more source

Enhanced recovery after surgery protocols in gastrectomy with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer. [PDF]

World J Clin Oncol
Nampoolsuksan C, Parakonthun T.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy

Surgical Clinics of North America, 2020
Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy is an aggressive, potentially curative approach used to treat locoregional disease associated with primary and secondary malignancies of the peritoneum. It involves resection of all macroscopic disease larger than 2.5 mm, followed by instillation of hyperthermic chemotherapy ...
Eric, Pletcher, Elizabeth, Gleeson, Daniel, Labow   +2 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy

Advances in Anesthesia, 2005
Cancer treatment frequently requires a multimodality approach, involving surgical resection(s), radiotherapy, and chemotherapy. Advanced surgical approaches allow for the combination of two of these, offering patients intraoperative radiotherapy with surgical resection or intraoperative chemotherapy targeted and limited to a particular body region. The
Alicia M. Kowalski, Thomas B. Dougherty
openaire   +1 more source

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Annals of Surgical Oncology, 2023
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality
Julia H, Gelissen, Naomi N, Adjei, Blair, McNamara, Levent, Mutlu, Justin A, Harold, Mitchell, Clark, Gary, Altwerger, Peter R, Dottino, Gloria S, Huang, Alessandro D, Santin, Masoud, Azodi, Elena, Ratner, Peter E, Schwartz, Vaagn, Andikyan   +13 more
openaire   +2 more sources

Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer

JAAPA, 2021
ABSTRACT Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for decades as a treatment for disseminated abdominal malignancies, including pseudomyxoma peritonei and peritoneal mesothelioma. HIPEC had been used to treat recurrent ovarian cancer only when curative options were lacking, but new data indicate that it may be suitable ...
Shilpa, Gajarawala, Jessica, Pelkowski, Rose, Dorian, Amanda, Stanton, Tri, Dinh   +4 more
openaire   +2 more sources